Phio Pharmaceuticals Corp
PHIO
NASDAQ
Biotechnology
$1.09
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $12.60M
Volume 93.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-12.90M
TTM
-82.1%
YoY
Operating Cash Flow
$-12.20M
TTM
-70.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.2 | 1.3 | 1.1 | 1.4 | 1.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.3 | 2.5 | 2.5 | 4.2 | 4.3 |
Operating Income | -2.3 | -2.5 | -2.5 | -4.2 | -4.3 |
EBITDA | -2.3 | -2.5 | -2.5 | -4.2 | -4.3 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 |
Income Before Income Taxes | -2.2 | -2.4 | -2.4 | -4.0 | -4.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.2 | -2.4 | -2.4 | -4.0 | -4.1 |
Consolidated Net Income / Loss | -2.2 | -2.4 | -2.4 | -4.0 | -4.1 |
Net Income Attributable to Common Shareholders | -2.2 | -2.4 | -2.4 | -4.0 | -4.1 |
Basic EPS | -$0.45 | -$0.44 | -$0.25 | -$0.34 | -$0.36 |
Diluted EPS | -$0.45 | -$0.44 | -$0.25 | -$0.34 | -$0.36 |
Basic Shares Outstanding | 4.8M | 5.5M | 9.4M | 11.6M | 11.6M |
Diluted Shares Outstanding | 4.8M | 5.5M | 9.4M | 11.6M | 11.6M |